We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| (MM) | NASDAQ:RCPT | NASDAQ | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 231.96 | 0.00 | 01:00:00 |
From Jul 2019 to Jul 2024
| Wedbush Life Sciences Management Access Conference |
| Hotel: Le Parker Meridien Hotel in New York City |
| Time: Wednesday, August 14, 2013 at 8:00 a.m. Eastern |
| Canaccord Genuity Growth Conference |
| Hotel: Intercontinental in Boston |
| Time: Thursday, August 15, 2013 at 10:00 a.m. Eastern |
To listen to a live webcast or a replay of either presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 7 days after the event.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
Hot Features
Premium
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
1 Year RECEPTOS, INC. Chart |
1 Month RECEPTOS, INC. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
